Daiken Biomedical Co., Ltd. (TPE:7780)
Taiwan · Delayed Price · Currency is TWD 16.95
-0.10 (-0.59%)
At close: Aug 28, 2026
Daiken Biomedical Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Cash & Equivalents | 5,261 | 2,236 | 1,140 | 287.07 | 243.71 |
Cash & Short-Term Investments | 5,261 | 2,236 | 1,140 | 287.07 | 243.71 |
Cash Growth | 342.47% | 96.21% | 297.03% | 17.79% | - |
Accounts Receivable | 141.86 | 136.32 | 93.5 | 68.19 | 53.54 |
Other Receivables | 4.85 | 7.27 | 0.65 | 3.33 | - |
Receivables | 146.7 | 143.59 | 94.15 | 71.51 | 53.54 |
Inventory | 529 | 416 | 245.71 | 262.65 | 178.36 |
Prepaid Expenses | 51.38 | 41.41 | 31.89 | 19.39 | 17.58 |
Other Current Assets | - | 3,026 | - | 92.12 | 30.71 |
Total Current Assets | 5,988 | 5,863 | 1,511 | 732.73 | 523.9 |
Property, Plant & Equipment | 17.64 | 19.25 | 3.28 | - | - |
Other Intangible Assets | 3.14 | 3.96 | 3.74 | 1.46 | 1.09 |
Long-Term Deferred Tax Assets | 16.74 | 13.07 | 11.69 | 6.53 | - |
Other Long-Term Assets | 151.69 | 13.3 | 7.62 | 4.45 | 5.18 |
Total Assets | 6,177 | 5,913 | 1,538 | 745.17 | 530.17 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Accounts Payable | 156.56 | 154.33 | 73.75 | 53.15 | 32.4 |
Accrued Expenses | 72.76 | 80.7 | 63.24 | 89.3 | 87.6 |
Short-Term Debt | 100 | 100 | - | 158 | 33 |
Current Portion of Long-Term Debt | - | - | - | 69.02 | 41.63 |
Current Portion of Leases | 3.24 | 3.2 | 1.82 | - | - |
Current Income Taxes Payable | 77.16 | 63.92 | 9.37 | 28.15 | 19.36 |
Current Unearned Revenue | 13.31 | 10.18 | 7.26 | 30.23 | 21.46 |
Other Current Liabilities | 837.85 | 34.54 | 74.93 | 20.45 | 5.91 |
Total Current Liabilities | 1,261 | 446.87 | 230.37 | 448.29 | 241.37 |
Long-Term Debt | - | - | - | 49.56 | 61.37 |
Long-Term Leases | 13.55 | 15.18 | 0.45 | - | - |
Long-Term Deferred Tax Liabilities | 31.15 | 7.9 | - | - | - |
Total Liabilities | 1,306 | 469.95 | 230.81 | 497.85 | 302.74 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Common Stock | 810.02 | 810.02 | 600.02 | 155.4 | 155.4 |
Additional Paid-In Capital | 3,815 | 4,415 | 624.06 | - | - |
Retained Earnings | 204.66 | 179.86 | 83.76 | 91.92 | 72.03 |
Comprehensive Income & Other | 124.59 | 37.87 | -0.86 | - | - |
Shareholders' Equity | 4,872 | 5,443 | 1,307 | 247.32 | 227.43 |
Total Liabilities & Equity | 6,177 | 5,913 | 1,538 | 745.17 | 530.17 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Total Debt | 116.79 | 118.37 | 2.27 | 276.58 | 136 |
Net Cash (Debt) | 5,144 | 2,118 | 1,137 | 10.49 | 107.71 |
Net Cash Growth | 332.86% | 86.20% | 10746.37% | -90.26% | - |
Net Cash Per Share | 6.66 | 3.17 | 2.59 | 0.05 | 0.69 |
Filing Date Shares Outstanding | 805.56 | 810.02 | 600.02 | 155.4 | 155.4 |
Total Common Shares Outstanding | 805.56 | 810.02 | 600.02 | 155.4 | 155.4 |
Working Capital | 4,727 | 5,416 | 1,281 | 284.44 | 282.53 |
Book Value Per Share | 6.05 | 6.72 | 2.18 | 1.59 | 1.46 |
Tangible Book Value | 4,869 | 5,439 | 1,303 | 245.86 | 226.34 |
Tangible Book Value Per Share | 6.04 | 6.71 | 2.17 | 1.58 | 1.46 |